全文获取类型
收费全文 | 420556篇 |
免费 | 27685篇 |
国内免费 | 2919篇 |
专业分类
耳鼻咽喉 | 5544篇 |
儿科学 | 9537篇 |
妇产科学 | 11180篇 |
基础医学 | 58741篇 |
口腔科学 | 12534篇 |
临床医学 | 36720篇 |
内科学 | 86019篇 |
皮肤病学 | 9219篇 |
神经病学 | 31001篇 |
特种医学 | 14858篇 |
外国民族医学 | 82篇 |
外科学 | 64562篇 |
综合类 | 10494篇 |
现状与发展 | 1篇 |
一般理论 | 120篇 |
预防医学 | 22675篇 |
眼科学 | 9993篇 |
药学 | 33633篇 |
1篇 | |
中国医学 | 2261篇 |
肿瘤学 | 31985篇 |
出版年
2021年 | 3462篇 |
2019年 | 3573篇 |
2018年 | 5505篇 |
2017年 | 4134篇 |
2016年 | 4269篇 |
2015年 | 4935篇 |
2014年 | 6991篇 |
2013年 | 9362篇 |
2012年 | 12907篇 |
2011年 | 13231篇 |
2010年 | 7865篇 |
2009年 | 7265篇 |
2008年 | 12234篇 |
2007年 | 13120篇 |
2006年 | 13019篇 |
2005年 | 11884篇 |
2004年 | 11316篇 |
2003年 | 10916篇 |
2002年 | 10446篇 |
2001年 | 28726篇 |
2000年 | 29197篇 |
1999年 | 24146篇 |
1998年 | 5645篇 |
1997年 | 4680篇 |
1996年 | 4210篇 |
1995年 | 3833篇 |
1994年 | 3438篇 |
1993年 | 3156篇 |
1992年 | 16378篇 |
1991年 | 15094篇 |
1990年 | 14430篇 |
1989年 | 14213篇 |
1988年 | 12845篇 |
1987年 | 12308篇 |
1986年 | 11295篇 |
1985年 | 10548篇 |
1984年 | 7154篇 |
1983年 | 5843篇 |
1982年 | 2965篇 |
1981年 | 2433篇 |
1979年 | 5658篇 |
1978年 | 3486篇 |
1977年 | 3097篇 |
1975年 | 2731篇 |
1974年 | 3186篇 |
1973年 | 2975篇 |
1972年 | 2900篇 |
1971年 | 2836篇 |
1970年 | 2579篇 |
1969年 | 2596篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
Fear of falling, defined as a lack of self-confidence that one may avoid falls while doing everyday activities, may have serious consequences for elderly people. This article examines the prevalence, risk factors, and consequences of fear of falling in the elderly population; methods for assessing those fears; and suggests evidence-based interventions. Incorporating successful strategies into programs to reduce falling can result in improved patient outcomes as well as decreased healthcare utilization and costs. 相似文献
993.
994.
W.-S. Ahn D.-J. Kim† G.-T. Chae‡ J.-M. Lee S.-M. Bae§ J.-I. Sin§ Y.-W. Kim§ S.-E. Namkoong & I. P. Lee 《International journal of gynecological cancer》2004,14(4):589-594
A mushroom extract, Agaricus blazei Murill Kyowa (ABMK), has been reported to possess antimutagenic and antitumor effects. Here, we investigate the beneficial effects of ABMK consumption on immunological status and qualities of life in cancer patients undergoing chemotherapy. One hundred cervical, ovarian, and endometrial cancer patients were treated either with carboplatin (300 mg / m(2)) plus VP16 (etoposide, 100 mg / m(2)) or with carboplatin (300 mg / m(2)) plus taxol (175 mg / m(2)) every 3 weeks for at least three cycles with or without oral consumption of ABMK. We observed that natural killer cell activity was significantly higher in ABMK-treated group (ANOVA, n = 39, P < 0.002) as compared with nontreated placebo group (n = 61). However, no significant difference in lymphokine-activated killer and monocyte activities was observed in a manner similar to the count of specific immune cell populations between ABMK-treated and nontreated groups. However, chemotherapy-associated side effects such as appetite, alopecia, emotional stability, and general weakness were all improved by ABMK treatment. Taken together, this suggests that ABMK treatment might be beneficial for gynecological cancer patients undergoing chemotherapy. 相似文献
995.
M.S. Ågren U. Ostenfeld M.E. Crawford K. Kiss Y. Gong C. Gluud A. FriisMøller F. Kallehave K. Raffn L.N. Jorgensen 《Wound repair and regeneration》2005,13(2):A1-A27
Extended healing time and lack of documented effective treatments of sacrococcygeal pilonidal disease create substantial problems. Locally applied zinc oxide has been reported to promote wound healing. We have compared topical zinc oxide (3%) with placebo meshes for pilonidal wounds healing by secondary intention in a randomized, double‐blind, placebo‐controlled multicenter trial. Sixty‐four consecutive patients, 53 males, aged between 18 and 60 years (median 26 years) with excised pilonidal wounds were centrally randomized to local zinc oxide (30 mg/g, n = 33) or to placebo (n = 31) mesh treatment. Patients were followed with strict recording of beneficial and harmful effects. The median healing times were 54 days (42–71 days, interquartile range, n = 33) for the zinc group and 62 days (55–82 days, n = 31) for the placebo group. This difference was not statistically different (p = 0.32). Based on Cox regression analysis initial wound volume influenced healing negatively (p = 0.016) while smoking (p = 0.011) was associated with faster wound healing. Significantly (p < 0.01) more placebo (n = 12) than zinc oxide‐treated patients (n = 3) needed antibiotics postoperatively. Although topical zinc oxide increased (p < 0.001) wound fluid zinc levels (1830 ± 405 μM, mean ± SEM) compared with placebo (3.1 ± 1.6 μM) serum‐zinc levels did not differ significantly between the zinc (13.5 ± 0.4 μM) and placebo (12.8 ± 0.4 μm) groups on postoperative day 7. No adverse events were recorded. Topical zinc oxide treatment did not accelerate time to closure of open pilonidal wounds but was associated with reduced antibiotic usage. 相似文献
996.
997.
998.
Padmaja Yalamanchili Eric Wexler Megan Hayes Ming Yu Jody Bozek Mikhail Kagan Heike S. Radeke Michael Azure Ajay Purohit David S. Casebier Simon P. Robinson 《Journal of nuclear cardiology》2007,14(6):782-788
Background
BMS-747158-02 is a novel fluorine 18-labeled pyridazinone derivative designed for cardiac imaging. The uptake and retention
mechanisms of F-18 BMS-747158-02 in cardiac myocytes were studied in vitro, and the biodistribution of F-18 BMS-747158-02
was studied in vivo in mice.
Methods and Results
Fluorine 19 BMS-747158-01 inhibited mitochondrial complex I (MC-I) in bovine heart submitochondrial particles with an IC50 of 16.6±3 nmol/L that was comparable to the reference inhibitors of MC-1, rotenone, pyridaben, and deguelin (IC50 of 18.2±6.7 nmol/L, 19.8±2.6 nmol/L, and 23.1±1.5 nmol/L, respectively). F-18 BMS-747158-02 had high uptake in monolayers
of neonatal rat cardiomyocytes (10.3%±0.7% of incubated drug at 60 minutes) that was inhibited by 200 nmol/L of rotenone (91%±2%)
and deguelin (89%±3%). In contrast, an inactive pyridaben analog, P-0 (IC50 value>4 μmol/L in MC-1 assay), did not inhibit the binding of F-18 BMS-747158-02 in cardiomyocytes. Uptake and washout kinetics
for F-18 BMS-747158-02 in rat cardiomyocytes indicated that the time to half-maximal (t1/2) uptake was very rapid (approximately 35 seconds), and washout t1/2 for efflux of F-18 BMS-747158-02 was greater than 120 minutes. In vivo biodistribution studies in mice showed that F-18 BMS-747158-02
had substatial myocardial uptake (9.5%±0.5% of injected dose per gram) at 60 minutes and heart-to-lung and heart-to-liver
ratios of 14.1±2.5 and 8.3±0.5, respectively. Positron emission tomography imaging in the mouse allowed clear cardiac visualization
and demonstrated sustained myocardial uptake through 55 minutes.
Conclusions
F-18 BMS-747158-02 is a novel positron emission tomography cardiac tracer targeting MC-I in cardiomyocytes with rapid uptake
and slow washout. These characteristics allow fast and sustained accumulation in the heart. 相似文献
999.
1000.